IFNA1 and cryohydrocytosis: [8–10] Based on its efficacy and safety compared to that of IFN-based therapy, DCV + ASV combination therapy was the first IFN-free regimen reimbursed by national health insurance in Korea for the treatment of genotype 1b CHC.